Processing

Please wait...

Settings

Settings

Goto Application

1. WO1992015602 - CANCER DIAGNOSIS AND THERAPY

Publication Number WO/1992/015602
Publication Date 17.09.1992
International Application No. PCT/US1992/001624
International Filing Date 28.02.1992
Chapter 2 Demand Filed 21.08.1992
IPC
A61K 38/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C07K 14/47 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
C12Q 1/68 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
G01N 33/50 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
G01N 33/574 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
C12Q 1/6841
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6813Hybridisation assays
6841In situ hybridisation
C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
C12Q 2600/106
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
C12Q 2600/136
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
136Screening for pharmacological compounds
Applicants
  • DANA-FARBER CANCER INSTITUTE, INC. [US]/[US]
Inventors
  • SAGER, Ruth
Agents
  • FRASER, Janis, K.
Priority Data
662,21628.02.1991US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CANCER DIAGNOSIS AND THERAPY
(FR) DIAGNOSTIC ET THERAPIE DU CANCER
Abstract
(EN)
A method for determining the presence of cancerous cells in a tissue from a patient, which method includes the steps of providing either (a) a nucleic acid probe including a nucleotide sequence at least 8 nucleotides in length which is identical to a portion or all of the coding sequence of a candidate tumor suppressor gene, or (b) an antibody specific for a candidate tumor suppressor gene product; obtaining from a patient a first tissue sample potentially including cancerous cells; providing a second tissue sample, substantially all of the cells of which are non-cancerous; and comparing, by use of either the probe or the antibody, the levels of expression of the candidate tumor suppressor gene in the first and second tissue sample, wherein an amount of hybridization or immune complex formation, as the case may be, in the first tissue sample less than one third that in the second tissue sample indicates the presence of cancerous cells in the first tissue sample; methods of treating a cancerous cell by increasing the level of expression of a candidate tumor suppression gene in the cell; novel candidate tumor suppressor genes; and their use in diagnosis and therapy.
(FR)
Procédé de détermination de la présence de cellules cancéreuses dans des tissus d'un patient, ledit procédé comprend les étapes consistant à produire soit (a) une sonde d'acide nucléique comprenant une séquence de nucléotides d'une longueur d'au moins 8 nucléotides laquelle est identique à tout ou partie de la séquence codante d'un gène suppresseur de tumeur potentielle, soit (b) un aniticorps spécifique d'un produit génique suppresseur de tumeur potentielle; à prélever sur la patient un premier échantillon de tissu comprenant potentiellement des cellules cancéreuses; à recueillir un second échantillon de tissu dont toutes les cellules sont non cancéreuses; et à comparer, au moyen soit de la sonde soit de l'anticorps, les niveaux d'expression du gène suppresseur de tumeur potentielle dans les premiers et seconds échantillons de tissu, dans lesquels une quantité d'hybridation ou de formation de complexe immun, comme cela peut être le cas, dans le premier échantillon de tissu, inférieure à un tiers de celle ayant lieu dans le second échantillon de tissu indique la présence de cellules cancéreuses dans le premier échantillon de tissu. L'invention concerne également des procédés de traitement d'une cellule cancéreuse par augmentation du niveau d'expression d'un gène de suppression de tumeur potentielle dans la cellule, ainsi qu'un nouveau gène suppresseur de tumeur potentielle et leur utilisation en diagnostic ainsi qu'en thérapie.
Also published as
Latest bibliographic data on file with the International Bureau